Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 26.34 4.61% 1.16
GTHX closed up 4.61 percent on Friday, January 19, 2018, on 60 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical GTHX trend table...

Date Alert Name Type % Chg
Jan 19 Upper Bollinger Band Walk Strength 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Above Upper BB Strength 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 19 Up 3 Days in a Row Strength 0.00%
Jan 19 Upper Bollinger Band Touch Strength 0.00%
Jan 18 Upper Bollinger Band Walk Strength 4.61%
Jan 18 Wide Bands Range Expansion 4.61%
Jan 18 Above Upper BB Strength 4.61%
Jan 18 Overbought Stochastic Strength 4.61%

Older signals for GTHX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Is GTHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.67
52 Week Low 12.04
Average Volume 164,596
200-Day Moving Average 0.0
50-Day Moving Average 20.5786
20-Day Moving Average 21.1175
10-Day Moving Average 22.498
Average True Range 1.2872
ADX 24.19
+DI 41.9
-DI 10.77
Chandelier Exit (Long, 3 ATRs ) 22.9984
Chandelier Exit (Short, 3 ATRs ) 22.2516
Upper Bollinger Band 25.3817
Lower Bollinger Band 16.8533
Percent B (%b) 1.11
BandWidth 40.385462
MACD Line 1.2225
MACD Signal Line 0.5558
MACD Histogram 0.6667
Fundamentals Value
Market Cap 745.03 Million
Num Shares 28.3 Million
EPS -11.02
Price-to-Earnings (P/E) Ratio -2.39
Price-to-Sales 0.00
Price-to-Book 4.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.06
Resistance 3 (R3) 29.82 28.34 29.44
Resistance 2 (R2) 28.34 27.39 28.46 29.23
Resistance 1 (R1) 27.34 26.81 27.84 27.58 29.03
Pivot Point 25.86 25.86 26.11 25.98 25.86
Support 1 (S1) 24.86 24.91 25.36 25.10 23.65
Support 2 (S2) 23.38 24.33 23.50 23.45
Support 3 (S3) 22.38 23.38 23.24
Support 4 (S4) 22.62